Development of electron-beam equipment and technology of layer welding of the wire in the conditions of additive technologies

Immunotoxins are powerful tools to specifically eliminate deviated cells. Due to the side effects of the original immunotoxins, they were only considered for the treatment of cancer as in these cases, the potential favourable effect outweighed the unwanted toxic side effects. Over time, many improvements in the construction of immunotoxins have been implemented that circumvent, or at least strongly diminish, the side effects. In consequence this opens the way to employ these immunotoxins for the treatment of non-life threatening diseases. One such category of disease could be the many chronic inflammatory disorders in which an uncontrolled interaction between inflammatory cells leads to chronicity. In several of these chronic conditions, activated macrophages, which are characterised by an increased expression of CD64, are known to play a key role. In this review we discus the data presently available on elimination of activated macrophages through CD64 immunotoxins in several animal models for chronic disease. A chemically linked complete antibody with the plant toxin Ricin-A, proved very effective and provided proof of concept. Subsequently, the development towards genetically engineered, fully human, multivalent single chain based immunotoxins that have diminished immunogenicity, is discussed. The data show that the specific elimination of activated macrophages through CD64 is indeed beneficial for the course of disease. As opposed to other methods used to inactivate or eliminate macrophages, with the CD64 based immunotoxins only the activated population is killed. This may open the way to apply these immunotoxins as therapeutics in chronic inflammatory disease

Evaluation of the ESBL-coding plasmids transmissibility in E. coli isolated from ambulatory patient's urina

Representatives of the Enterobacteriaceae family are the main causative agents of urinary tract infections. Escherichia coli can exhibit resistance to [beta] -lactam antibiotics by synthesizing ESBL (extended spectrum [beta]-lactamases). CTX-M [beta] -lactamases are the dominant group of ESBL. In this paper, we investigated the ability of E. coli urinary isolates to transmit resistance genes within the plasmid. An analysis of the effectiveness of conjugation has shown that E. coli strains producing ESBL are capable of transferring resistance genes to a recipient bacterium at a high frequency

Горизонтальные классификаторы. Основы теории и расчета: моногр.

Приведены технологические схемы получения строительных песков при гидромеханизированной добыче, основные конструктивные схемы классификаторов, используемых при получении строительных песков. Особое внимание уделено изучению процесса взаимодействия проточной части горизонтального классификатора с совокупностью твердых частиц, расположенных в горизонтальном ускоренном потоке несущей среды. Выполнено математическое моделирование ускоренного движения горизонтального потока и твердых частиц в пределах разнонаклонных поверхностей горизонтального классификатора. Экспериментально изучено гравитационное осаждение твердых частиц, рассмотренное в виде вертикальной и горизонтальной составляющих, а также влияние стесненности движения и перемещения твердых частиц относительно несущего горизонтального потока. Приведена методика расчета и выбора параметров классификаторов, информация об опыте проектирования и внедрения горизонтальных классификаторов в составе добычных комплексов при освоении обводненных месторождений песков. Монография может быть полезна студентам, инженерно-техническим работникам, сотрудникам высших учебных заведений, научно-исследовательских институтов и проектных организаций горной промышленности

Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Once Daily Empagliflozin 25 mg for the Treatment of Postprandial Hypoglycemia After Roux-en-Y Gastric Bypass

Aims: To investigate the effect of empagliflozin on glucose dynamics in individuals suffering from postbariatric hypoglycemia (PBH) after Roux-en-Y gastric bypass (RYGB). Methods: Twenty-two adults with PBH after RYGB were randomized to empagliflozin 25 mg or placebo once daily over 20 days in a randomized, double-blind, placebo-controlled, crossover trial. The primary efficacy outcome was the amplitude of plasma glucose excursion (peak to nadir) during a mixed-meal tolerance test (MMTT). Outcomes of the outpatient period were assessed using continuous glucose monitoring (CGM) and an event-tracking app. Results: The amplitude of glucose excursion during the MMTT was 8.1 ± 2.4 mmol/L with empagliflozin versus 8.1 ± 2.6 mmol/L with placebo (mean ± standard deviation, P = 0.807). CGM-based mean amplitude of glucose excursion during the 20-day period was lower with empagliflozin than placebo (4.8 ± 1.3 vs. 5.2 ± 1.6. P = 0.028). Empagliflozin reduced the time spent with CGM values >10.0 mmol/L (3.8 ± 3.5% vs. 4.7 ± 3.8%, P = 0.009), but not the time spent with CGM values <3.0 mmol/L (1.7 ± 1.6% vs. 1.5 ± 1.5%, P = 0.457). No significant difference was observed in the quantity and quality of recorded symptoms. Eleven adverse events occurred with empagliflozin (three drug-related) and six with placebo. Conclusions: Empagliflozin 25 mg reduces glucose excursions but not hypoglycemia in individuals with PBH

Obesity as Assessed by Body Adiposity Index and Multivariable Cardiovascular Disease Risk

To assess the role of body adiposity index (BAI) in predicting cardiovascular disease (CVD) and coronary heart disease (CHD) mortality, in comparison with body mass index (BMI), waist circumference (WC), and the waist circumference to hip circumference ratio (WHR). This study was a prospective 15 year mortality follow-up of 4175 Australian males, free of heart disease, diabetes and stroke. The Framingham Risk Scores (FRS) for CHD and CVD death were calculated at baseline for all subjects. Multivariable logistic regression was used to assess the effects of the measures of obesity on CVD and CHD mortality, before adjustment and after adjustment for FRS. The predictive ability of BAI, though present in the unadjusted analyses, was generally not significant after adjustment for age and FRS for both CVD and CHD mortality. BMI behaved similarly to BAI in that its predictive ability was generally not significant after adjustments. Both WC and WHR were significant predictors of CVD and CHD mortality and remained significant after adjustment for covariates. BAI appeared to be of potential interest as a measure of % body fat and of obesity, but was ineffective in predicting CVD and CHD